Zepbound
The latest news about Zepbound: headlines, AI summaries and the full story from every source.
- Eli Lilly's Upcoming Earnings Report and the Significance of Retatrutide
- GLP-1 Drugs Are Changing Eating Habits and Impacting Food Industry Revenue
- Combining Eli Lilly's Taltz and Zepbound May Improve Psoriasis and Metabolic Benefits
- Eli Lilly Announces Promising Weight Loss Drug Combination
- Eli Lilly Halts Development of an Obesity Drug Amid High Standards and Strategic Diversification
- Eli Lilly and Novo Nordisk Compete Over Next-Phase Obesity Drug Innovations
- Eli Lilly's Momentum Faces Potential Threat from Competitive GLP-1 Market
- Eli Lilly Releases Study Showing Zepbound May Reduce Healthcare Costs
- Eli Lilly Study Shows Zepbound May Reduce Healthcare Costs
- Eli Lilly's Weight-Loss Drug Revenue Grows Despite Decline in GLP-1 Insurance Coverage
- Ken Griffin Increases Stake in Eli Lilly Amid Strong Performance
- Oral Wegovy Surpasses Eli Lilly's Zepbound as Top-Selling Weight-Loss Drug
- Eli Lilly's Weight-Loss and Diabetes Drugs Contribute Over Two-Thirds of Q1 Revenue
- Rising Use of GLP-1 Drugs Benefits Eli Lilly
- Eli Lilly Shares Reach Record High Amid Regulatory and Market Developments
- Eli Lilly's GLP-1 Drugs Face Potential Coverage Reduction by Employers
- CVS Health Announces Coverage of Eli Lilly's Weight Management Medicines
- Eli Lilly Aims to Leverage GLP-1 Success for Future Acquisitions
- Eli Lilly's Continued Growth Driven by GLP-1 Expansion and Strategic Acquisitions
- Novo Nordisk Stock Faces Challenges Amid Competition and Clinical Setbacks
- Eli Lilly's Retatrutide Shows Strong Weight-Loss Results as Next-Gen Therapy
- Eli Lilly CEO's Comments on Foundayo Spark Optimism Among Investors
- Eli Lilly Achieves Coverage of All Obesity Medicines by Major U.S. Pharmacy Benefit Managers
- Eli Lilly CEO Comments on Foundayo Spark Optimism Among Investors
- CVS Health Restores Coverage for Eli Lilly’s Zepbound and Adds Obesity Pill
- Eli Lilly Reports Strong Q1 Earnings and Raises Full-Year Guidance Amid Mounjaro Growth
- Novo Nordisk Reports High-Dose Wegovy Achieves Nearly 28% Weight Loss in Some Patients
- Eli Lilly's Mounjaro Becomes the World's Best-Selling Drug
- Eli Lilly Announces Positive News for Shareholders Amid Weight Loss Drug Market Growth
- Eli Lilly's GLP-1 Drugs Drive Revenue Growth, With Potential for Further Expansion
- Eli Lilly Reports Strong Earnings Growth Driven by Weight Loss Drugs
- Eli Lilly Reports 56% Revenue Surge Amid Strong Demand for GLP-1 Drugs
- Eli Lilly Raises Annual Profit Forecast Due to Strong Demand for GLP-1 Drugs
- Eli Lilly to Report First-Quarter Earnings Ahead of Market Open